|
gptkbp:instanceOf
|
gptkb:oxazolidinone
gptkb:antibiotic
|
|
gptkbp:approvalYear
|
2000
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J01XX08
|
|
gptkbp:brand
|
gptkb:Zyvox
|
|
gptkbp:CASNumber
|
165800-03-3
|
|
gptkbp:contraindication
|
concurrent use with monoamine oxidase inhibitors (MAOIs)
|
|
gptkbp:discoveredBy
|
gptkb:Pharmacia_&_Upjohn
|
|
gptkbp:eliminationHalfLife
|
5-7 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C16H20FN3O4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
linezolid
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
31%
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
gptkb:serotonin_syndrome
peripheral neuropathy
thrombocytopenia
lactic acidosis
|
|
gptkbp:usedFor
|
treatment of vancomycin-resistant Enterococcus (VRE)
treatment of methicillin-resistant Staphylococcus aureus (MRSA)
treatment of infections caused by Gram-positive bacteria
|
|
gptkbp:bfsParent
|
gptkb:Zyvox
|
|
gptkbp:bfsLayer
|
5
|